Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will...
The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen ® and advancing...
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will...
Niagen Bioscience: Q1 Earnings Snapshot
Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from...
Barchart Research What to Expect from NAGE Earnings NAGE Generated May 5, 2026 Current Price $4.82 EPS Estimate $$0.06 Consensus Rating Strong Buy Average Move 20.64% Niagen Bioscience's Revenue Momentum...
New telehealth platform introduces prescription-only Niagen At-Home Injection Kit, expanding access to pharmaceutical-grade NAD+ support for cellular and tissue health delivered directly to eligible patients'...
Partnership unlocks Olympia’s established clinic network for Niagen Plus, expands pharmaceutical-grade Niagen supply chain, and brings liquid compounded vials to market
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference...
NR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience’s leadership in NAD+ science and ingredient quality